利用新型细胞平台优化用于艾滋病基因治疗的CRISPR/CAS9技术。 - Suppr

Suppr

超能文献

Using a novel cellular platform to optimize CRISPR/CAS9 technology for the gene therapy of AIDS.

作者信息

He Jingjin, Zhang Thanutra, Fu Xuemei

机构信息

The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518033, China.

Division of Biological Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.

出版信息

Protein Cell. 2017 Nov;8(11):848-852. doi: 10.1007/s13238-017-0453-z.

DOI:10.1007/s13238-017-0453-z

PMID:28822100

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5676591/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1fa/5676591/8cee2c110e52/13238_2017_453_Fig1_HTML.jpg

相似文献

Using a novel cellular platform to optimize CRISPR/CAS9 technology for the gene therapy of AIDS.

Protein Cell. 2017 Nov;8(11):848-852. doi: 10.1007/s13238-017-0453-z.

Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.

Gene Ther. 2017 Jul;24(7):377-384. doi: 10.1038/gt.2017.35. Epub 2017 Jun 1.

CRISPR/Cas9 genome engineering in hematopoietic cells.

Drug Discov Today Technol. 2018 Aug;28:33-39. doi: 10.1016/j.ddtec.2018.08.001. Epub 2018 Aug 25.

CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.

Sci China Life Sci. 2017 May;60(5):468-475. doi: 10.1007/s11427-017-9057-2. Epub 2017 Apr 20.

CRISPR (Clustered Regularly Interspaced Palindromic Repeat)/Cas9 System: A Revolutionary Disease-Modifying Technology.

Circulation. 2016 Sep 13;134(11):777-9. doi: 10.1161/CIRCULATIONAHA.116.024007.

CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.

Chem Rev. 2017 Aug 9;117(15):9874-9906. doi: 10.1021/acs.chemrev.6b00799. Epub 2017 Jun 22.

In vivo gene therapy potentials of CRISPR-Cas9.

Gene Ther. 2016 Jul;23(7):557-9. doi: 10.1038/gt.2016.25. Epub 2016 Mar 31.

[CRISPR-Cas system as molecular scissors for gene therapy].

Z Rheumatol. 2017 Feb;76(1):46-49. doi: 10.1007/s00393-017-0267-7.

Application of CRISPR/Cas9 genome editing to the study and treatment of disease.

Arch Toxicol. 2015 Jul;89(7):1023-34. doi: 10.1007/s00204-015-1504-y. Epub 2015 Apr 1.

Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.

Cancer Lett. 2016 Apr 1;373(1):109-118. doi: 10.1016/j.canlet.2016.01.030. Epub 2016 Jan 21.

本文引用的文献

2017 Update of the Drug Resistance Mutations in HIV-1.

Top Antivir Med. 2016 Dec;24(4):132-133.

Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.

Nat Biotechnol. 2015 Sep;33(9):985-989. doi: 10.1038/nbt.3290. Epub 2015 Jun 29.

Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.

Cell Stem Cell. 2014 Nov 6;15(5):643-52. doi: 10.1016/j.stem.2014.10.004.

Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.

Cell Stem Cell. 2014 Jul 3;15(1):27-30. doi: 10.1016/j.stem.2014.04.020.

Development and applications of CRISPR-Cas9 for genome engineering.

Cell. 2014 Jun 5;157(6):1262-1278. doi: 10.1016/j.cell.2014.05.010.

CRISPR-Cas systems for editing, regulating and targeting genomes.

Nat Biotechnol. 2014 Apr;32(4):347-55. doi: 10.1038/nbt.2842. Epub 2014 Mar 2.

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Cell. 2013 Sep 12;154(6):1380-9. doi: 10.1016/j.cell.2013.08.021. Epub 2013 Aug 29.

Nature, nurture and HIV: The effect of producer cell on viral physiology.

Virology. 2013 Sep 1;443(2):208-13. doi: 10.1016/j.virol.2013.05.023. Epub 2013 Jun 5.

Use of tissue culture cell lines to evaluate HIV antiviral resistance.

AIDS Res Hum Retroviruses. 2008 Jul;24(7):957-67. doi: 10.1089/aid.2007.0242.

Genotoxicity of retroviral integration in hematopoietic cells.

Mol Ther. 2006 Jun;13(6):1031-49. doi: 10.1016/j.ymthe.2006.03.001. Epub 2006 Apr 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Using a novel cellular platform to optimize CRISPR/CAS9 technology for the gene therapy of AIDS.

Protein Cell. 2017 Nov;8(11):848-852. doi: 10.1007/s13238-017-0453-z.

Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.

Gene Ther. 2017 Jul;24(7):377-384. doi: 10.1038/gt.2017.35. Epub 2017 Jun 1.

CRISPR/Cas9 genome engineering in hematopoietic cells.

Drug Discov Today Technol. 2018 Aug;28:33-39. doi: 10.1016/j.ddtec.2018.08.001. Epub 2018 Aug 25.

CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.

Sci China Life Sci. 2017 May;60(5):468-475. doi: 10.1007/s11427-017-9057-2. Epub 2017 Apr 20.

CRISPR (Clustered Regularly Interspaced Palindromic Repeat)/Cas9 System: A Revolutionary Disease-Modifying Technology.

Circulation. 2016 Sep 13;134(11):777-9. doi: 10.1161/CIRCULATIONAHA.116.024007.

CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.

Chem Rev. 2017 Aug 9;117(15):9874-9906. doi: 10.1021/acs.chemrev.6b00799. Epub 2017 Jun 22.

In vivo gene therapy potentials of CRISPR-Cas9.

Gene Ther. 2016 Jul;23(7):557-9. doi: 10.1038/gt.2016.25. Epub 2016 Mar 31.

[CRISPR-Cas system as molecular scissors for gene therapy].

Z Rheumatol. 2017 Feb;76(1):46-49. doi: 10.1007/s00393-017-0267-7.

Application of CRISPR/Cas9 genome editing to the study and treatment of disease.

Arch Toxicol. 2015 Jul;89(7):1023-34. doi: 10.1007/s00204-015-1504-y. Epub 2015 Apr 1.

Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.

Cancer Lett. 2016 Apr 1;373(1):109-118. doi: 10.1016/j.canlet.2016.01.030. Epub 2016 Jan 21.

本文引用的文献

2017 Update of the Drug Resistance Mutations in HIV-1.

Top Antivir Med. 2016 Dec;24(4):132-133.

Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.

Nat Biotechnol. 2015 Sep;33(9):985-989. doi: 10.1038/nbt.3290. Epub 2015 Jun 29.

Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.

Cell Stem Cell. 2014 Nov 6;15(5):643-52. doi: 10.1016/j.stem.2014.10.004.

Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.

Cell Stem Cell. 2014 Jul 3;15(1):27-30. doi: 10.1016/j.stem.2014.04.020.

Development and applications of CRISPR-Cas9 for genome engineering.

Cell. 2014 Jun 5;157(6):1262-1278. doi: 10.1016/j.cell.2014.05.010.

CRISPR-Cas systems for editing, regulating and targeting genomes.

Nat Biotechnol. 2014 Apr;32(4):347-55. doi: 10.1038/nbt.2842. Epub 2014 Mar 2.

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Cell. 2013 Sep 12;154(6):1380-9. doi: 10.1016/j.cell.2013.08.021. Epub 2013 Aug 29.

Nature, nurture and HIV: The effect of producer cell on viral physiology.

Virology. 2013 Sep 1;443(2):208-13. doi: 10.1016/j.virol.2013.05.023. Epub 2013 Jun 5.

Use of tissue culture cell lines to evaluate HIV antiviral resistance.

AIDS Res Hum Retroviruses. 2008 Jul;24(7):957-67. doi: 10.1089/aid.2007.0242.

Genotoxicity of retroviral integration in hematopoietic cells.

Mol Ther. 2006 Jun;13(6):1031-49. doi: 10.1016/j.ymthe.2006.03.001. Epub 2006 Apr 19.